ANRS, Emerging Infectious Diseases: Tuberculosis trials

The registry lists 12 Tuberculosis studies with ANRS, Emerging Infectious Diseases as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 2 2Phase 3 2Phase 4 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)RecruitingNCT06893757
• DRug Use & Infections in ViEtnam: TuBerculosis ControlRecruitingNCT05655702Not applicable
• Health and Migration Trajectories of Housekeepers in BamakoCompletedNCT05472051
• Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune SuppressionCompletedNCT04738812Phase 3
• Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment OnsetStatus unknownNCT04015713
• Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected PatientsStatus unknownNCT03941210
• Evaluation of an Innovative Tuberculosis Diagnostic TestStatus unknownNCT02573623
• Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT02273765Phase 3
• Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3CompletedNCT02057796Phase 4
• Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infectionStatus unknownNCT01986543Phase 2
• Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)CompletedNCT01331811Not applicable
• Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT00822315Phase 2